Using Australian Clinical Sites – Challenges for International Sponsors

21

description

Using Australian Clinical Sites – Challenges for International Sponsors. Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia. General Considerations. Australian Health Care System public and private sector providers supported by a federal Medicare system - PowerPoint PPT Presentation

Transcript of Using Australian Clinical Sites – Challenges for International Sponsors

Page 1: Using Australian Clinical Sites – Challenges for International Sponsors
Page 2: Using Australian Clinical Sites – Challenges for International Sponsors

Using Australian Clinical Sites – Challenges for

International Sponsors

Prof A J (Tony) WebberClinical Network Services Pty Ltd

Brisbane, Australia

Page 3: Using Australian Clinical Sites – Challenges for International Sponsors

General Considerations

Australian Health Care System• public and private sector providers• supported by a federal Medicare system• both sectors considered to provide quality

health care• major hospitals in both sectors exhibit a

strong commitment to medical research• many are experienced clinical trial sites• access to trained study/site coordinators

Page 4: Using Australian Clinical Sites – Challenges for International Sponsors

Australian Regulatory System

Two major Australian Government Bodies

• Therapeutics Goods Administration (TGA)

• The National Health and Medical Research Council (NH&MRC)

Page 5: Using Australian Clinical Sites – Challenges for International Sponsors

Therapeutic Goods Administration

• TGA – acts as Australia’s regulatory authority in relation to the registration and/or listing of pharmaceuticals, neutraceuticals, and medical devices

• Has adopted ICH GCP in principal – minor amendments concerning membership of Institutional Review Boards and comments concerning informed consent, retention of records and adverse drug reporting

Page 6: Using Australian Clinical Sites – Challenges for International Sponsors

National Health & Medical Research Council

• Allocates funds for health and medical research

• Provides health advice• Considers ethical issues • Regulates sensitive medical research

activities

Page 7: Using Australian Clinical Sites – Challenges for International Sponsors

Other Organizations

• Office of the Gene Technology Regulator (ORTG)• An additional level of approval for genetically modified

products

• Gene and Related Therapies Research Advisory Panel (GTRAP) • GTRAP is a subcommittee of the Research Committee, a

principal committee of the NHMRC.• Provides advice to Council on scientific, medical and

technical issues related to gene and related therapies, xenotransplantation and human stem cell research;

• Medicines Australia• Represents Australian pharmaceutical manufactures• Gives guidance on issues such as the form of indemnity

governing clinical trials and patient compensation

Page 8: Using Australian Clinical Sites – Challenges for International Sponsors

Approval for the Conduct of a Clinical Trial – The Sponsor

• The Sponsor of a clinical trial to be undertaken in Australia MUST be an Australian legal entity

• Contract Research Organizations holding a TGA “Enterprise Number” can perform the role of Australian Sponsor when an overseas company does not have Australian office or agent

Page 9: Using Australian Clinical Sites – Challenges for International Sponsors

Regulatory Approval to Conduct a Clinical Trial – Two Routes

Clinical Trial Notification (CTN)• 95% of all trials approved by the CTN

route• Onus on Human Research Ethics

Committees (HREC) for• ethical considerations • scientific merit/safety of the study.

• TGA will provide written acknowledgement within 10 days of receiving notification via a CTN form and appropriate payment.

• A separate CTN form for each site

Page 10: Using Australian Clinical Sites – Challenges for International Sponsors

Regulatory Approval to Conduct a Clinical Trial – Two Routes

Clinical Trial Exemption (CTX)• Sponsor submits an application to the

TGA for its evaluation and comment. • Review of clinical and pre clinical data is

required to be completed within 50 days.• This clock may be stopped for questions • Once approved, the study can then be

considered by HRECs and conducted at any number of sites

• If a HREC is concerned with scientific/ safety issues of a study submitted to it for CTN approval it can require that the study go through the CTX process

Page 11: Using Australian Clinical Sites – Challenges for International Sponsors

Clinical Trials in Australia- CTN Applications

650 727794

11091247

1597

1908

1710

1989

22352374 2378

0

500

1000

1500

2000

2500

1992-93 1993-94 1994-95 1995-96 1996-97 1997-98 1998-99 1999-00 2000-01 2001-02 2002-03 2003-04

Page 12: Using Australian Clinical Sites – Challenges for International Sponsors

Clinical Trials in Australia - CTX Applications

3337

23

9 9

3 3 4

8

5 2

0

5

10

15

20

25

30

35

40

1993-94 1994-95 1995-96 1996-97 1997-98 1998-99 1999-00 2000-01 2001-02 2002-03 2003-04

Page 13: Using Australian Clinical Sites – Challenges for International Sponsors

Summary of Australian Regulatory Process

ProcessCTN

(Clinical Trial Notification)

CTX(Clinical TrialExemption)

TGA Review

Not required

HREC Approval

Agency Timelines

7-14 days 30 days or 50 days

Fees $A240($US188)

$A15,300($US11,964)

% per year

99 1

CTX similar to IND

Page 14: Using Australian Clinical Sites – Challenges for International Sponsors

Ethics Approval

• Irrespective of route, CTN or CTX, all clinical trials must be submitted to an Australian Independent Ethics Committee, termed HRECs in Australia

• HRECs must comply with the requirements laid down by the NH&MRC who has a responsibility to oversee their operation

Page 15: Using Australian Clinical Sites – Challenges for International Sponsors

Approval Times

• Most HRECs and their Research Committees meet monthly

• Some will not meet December/January• Submission dates range from 2-6 weeks

before scheduled meetings• Approval between 5 weeks to 8 weeks

from submission to approval• Typically, overall process takes 8 13

weeks

Page 16: Using Australian Clinical Sites – Challenges for International Sponsors

Informed Consent Forms (ICF)

• Must conform with the particular HREC’s requirements (template) and ICH GCP

• Likely to require major changes from the sample ICF often provided by overseas sponsors

• Australian details on data protection, patient compensation and reimbursement must be included

Page 17: Using Australian Clinical Sites – Challenges for International Sponsors

Patient Recruitment Issues

• Payments• reimbursement all out of pocket

expenses associated with attending clinical trial visits – Must be approved by the HREC and detailed in the patient information sheets

• Advertising• Advertising and accelerated recruitment

strategies require HREC approval

Page 18: Using Australian Clinical Sites – Challenges for International Sponsors

Indemnity and Insurance

• The majority of HRECs have standardised on, and require sponsors to use, the “Form of Indemnity for Clinical Trials” published by Medicines Australia www.medicinesaustralia.com.au

• While clinical trial insurance may be held by the overseas sponsor, some Australian states require clinical trial insurance to be held by an Australian legal entity

Page 19: Using Australian Clinical Sites – Challenges for International Sponsors

Labelling Requirements

Major points• Name of the Sponsor – must be the

sponsor listed on the CTN form• Pharmaceutical dosage form,

administration route etc• Batch and/or code number• Trial subject identification – where

appropriate• Directions for use• “for clinical trial use only”

www.tga.gov.au/docs/pdf/unapproved/unapp.pdf

Page 20: Using Australian Clinical Sites – Challenges for International Sponsors

Study Close-out and Archiving

• Australian regulations stipulate records be retained for 15 years following completion of a clinical trial, or

• As per ICH GCP requirements, whichever is longer

• Investigational sites often request additional financial support from the sponsor for off site archiving by a third party or that the sponsor supports this process directly.

Page 21: Using Australian Clinical Sites – Challenges for International Sponsors

Thank you!